Pediatrics Anal Fissures Treatment With Polyethylene Glycol
Raktažodžiai
Santrauka
apibūdinimas
Anal fissure (AF) is common among children attending pediatric and surgery clinics and is frequently associated with painful defecation, stool withholding and constipation which affect 1%-30% of the pediatric population. Constipated children consume low fiber diets, come from lower socioeconomic families and tend to be obese. The reason why anal fissure develops is still largely unclear, however the pathogenesis points to an initial anal trauma cause by the hard stool leading to anal sphincter hypertonia or spasm which cause local ischemia and non-healing ulcer. It is not clear why the posterior anal canal is the most affected part by the local anal ischemia.
Current medical therapy for chronic anal fissure focuses on alleviating the two main pathologies by using anal sphincter relaxing topical ointments and laxative to treat associated constipation. The classical text book described treatment of AF focus on increasing fiber intake to treat the underlying constipation. Jensen et al, has found that treating the first episode of anal fissure with bran is more effective than local anesthetic or steroids. The American Society of Colon and Rectal Surgeons practice parameters suggest that increase in fluid and fiber ingestion, use of sitz baths, and if necessary use of stool softeners are safe have few side effects and should be the initial therapy for all patients with anal fissure.
There have been many recent randomized trials describing the effectiveness of Nitroglycerin (NTG), Botulinum toxin injection or the topical calcium channel blockers such as Diltiazem (DTZ) in adult and pediatric. A systematic review of the available randomized trials of these agents has shown that topical agents are marginally better than placebo [15]. Furthermore, in most trials that have demonstrated the effectiveness of topical agents laxatives usage was either not well controlled or lactulose was the main agent used. In children, many recent randomized trials have demonstrated the superior effectiveness of PEG over lactulose consequently; we think that treating AF with PEG is likely to improve the success rate and lead to persistent log-term fissure healing. Most adults and pediatric RCTs that have demonstrated the effectiveness of topical agents in healing AF, have focused on comparing various topical agents to placebo in treating AF, however the effectiveness in comparison to placebo has never been demonstrated in patients how are placed on more effective laxative such as PEG. We hypothesize that replacing lactulose with a more effective laxative such PEG as a sole agent to treat AF can eliminate the effectiveness and therefore the need to add topical sphincter relaxing agent such DTZ or NTG. Laxative-only treatment is likely to be more convenient and more cost-effective.
Datos
| Paskutinį kartą patikrinta: | 01/31/2016 |
| Pirmasis pateikimas: | 04/01/2015 |
| Numatytas registravimas pateiktas: | 04/15/2015 |
| Pirmas paskelbtas: | 04/16/2015 |
| Paskutinis atnaujinimas pateiktas: | 02/26/2016 |
| Paskutinis atnaujinimas paskelbtas: | 02/29/2016 |
| Faktinė studijų pradžios data: | 10/31/2014 |
| Numatoma pirminio užbaigimo data: | 10/31/2016 |
| Numatoma studijų užbaigimo data: | 10/31/2016 |
Būklė ar liga
Intervencija / gydymas
Drug: Polyethylene glycol
Drug: Polyethylene glycol with Diltiazem
Fazė
Rankų grupės
| Ranka | Intervencija / gydymas |
|---|---|
| Active Comparator: Polyethylene glycol In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study. | Drug: Polyethylene glycol Laxative to treat constipation |
| Active Comparator: Polyethylene glycol with Diltiazem Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study | Drug: Polyethylene glycol with Diltiazem Laxative and topical calcium channel blocker |
Tinkamumo kriterijai
| Tinkamos studijoms lytys | All |
| Priima sveikus savanorius | Taip |
| Kriterijai | Inclusion Criteria: 1. Painful defecation with visible anal fissure 2. Symptoms for 2 weeks 3. Children less than 14 years of age Exclusion Criteria: 1. Previous surgeries 2. Chronic illness affecting the rectum or perianal area 3. Refuse to participate |
Rezultatas
Pirminės rezultatų priemonės
1. Number of cases with healed anal fissure as detected by clinical physical exam [up to 8 weeks]
Antrinės rezultatų priemonės
1. Number cases with painless bowel movement detected during clinical visits or phone interviews [at 2,4 and 8 weeks]
2. Number of individuals with minimal or no straining during bowel movement detected during clinical visits or phone interviews [at 2, 4, and 8 weeks]
3. Number of cases that are passing soft bowel movements detected during clinical visits or phone interviews [at 2, 4, and 8 weeks]
4. Number of cases who are passing > 3 watery bowel movement (Diarrhea) detected during clinical visits or phone interviews [at 2, 4, and 8 weeks]
5. Compliance (number of cases who are taking the PEG and/or Diltiazem Ointment) as detected during clinical visits or phone interviews [2, 4, and 8 weeks]
